Evolent Health, Inc. EVH
We take great care to ensure that the data presented and summarized in this overview for Evolent Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EVH
View all-
Vanguard Group Inc Valley Forge, PA11.2MShares$110 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.69MShares$85.7 Million0.0% of portfolio
-
Glenn Welling Engaged Capital LLC | Newport Beach, Ca5.4MShares$53.3 Million14.4% of portfolio
-
Cadian Capital Management, LP New York, NY5.23MShares$51.5 Million3.41% of portfolio
-
William Blair Investment Management, LLC Chicago, IL4.78MShares$47.1 Million0.14% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.55MShares$44.9 Million0.98% of portfolio
-
Camber Capital Management LP Boston, MA4MShares$39.4 Million1.04% of portfolio
-
Granahan Investment Management, LLC Waltham, MA3.67MShares$36.2 Million1.95% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.58MShares$35.3 Million0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY3.19MShares$31.5 Million0.0% of portfolio
Latest Institutional Activity in EVH
Top Purchases
Top Sells
About EVH
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
Insider Transactions at EVH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 07
2025
|
Richard M Jelinek Director |
BUY
Open market or private purchase
|
Indirect |
30,000
+50.0%
|
$270,000
$9.13 P/Share
|
|
Mar 07
2025
|
Brendan B Springstubb Director |
BUY
Open market or private purchase
|
Direct |
15,000
+35.85%
|
$135,000
$9.27 P/Share
|
|
Mar 07
2025
|
Kim Keck Director |
BUY
Open market or private purchase
|
Direct |
10,540
+21.05%
|
$94,860
$9.44 P/Share
|
|
Mar 06
2025
|
Diane Holder Director |
BUY
Open market or private purchase
|
Direct |
2,735
+3.73%
|
$24,615
$9.33 P/Share
|
|
Mar 06
2025
|
Daniel Joseph Mc Carthy PRESIDENT |
BUY
Open market or private purchase
|
Direct |
11,040
+2.76%
|
$99,360
$9.01 P/Share
|
|
Mar 06
2025
|
Seth Blackley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
55,225
+6.76%
|
$497,025
$9.01 P/Share
|
|
Mar 06
2025
|
Peter J Grua Director |
BUY
Open market or private purchase
|
Direct |
11,040
+37.06%
|
$99,360
$9.01 P/Share
|
|
Mar 06
2025
|
Russell Monroe Glass Director |
BUY
Open market or private purchase
|
Direct |
5,400
+27.45%
|
$48,600
$9.27 P/Share
|
|
Mar 06
2025
|
Craig A. Barbarosh Director |
BUY
Open market or private purchase
|
Direct |
2,000
+5.89%
|
$16,000
$8.81 P/Share
|
|
Mar 04
2025
|
Brendan B Springstubb Director |
BUY
Open market or private purchase
|
Direct |
5,000
+29.69%
|
$40,000
$8.75 P/Share
|
|
Mar 03
2025
|
Brendan B Springstubb Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,842
+50.0%
|
-
|
|
Mar 03
2025
|
Emily Ann Rafferty Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,433
-1.84%
|
$19,464
$8.77 P/Share
|
|
Mar 03
2025
|
Emily Ann Rafferty Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
78,427
+20.22%
|
-
|
|
Mar 03
2025
|
Daniel Joseph Mc Carthy PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
39,501
-9.46%
|
$316,008
$8.77 P/Share
|
|
Mar 03
2025
|
Daniel Joseph Mc Carthy PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
244,268
+24.77%
|
-
|
|
Mar 03
2025
|
Jonathan Weinberg General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,544
-1.51%
|
$28,352
$8.77 P/Share
|
|
Mar 03
2025
|
Jonathan Weinberg General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
76,110
+13.49%
|
-
|
|
Mar 03
2025
|
Aammaad Shams Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,168
-4.03%
|
$25,344
$8.77 P/Share
|
|
Mar 03
2025
|
Aammaad Shams Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,801
+16.85%
|
-
|
|
Mar 03
2025
|
Seth Blackley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
72,768
-9.33%
|
$582,144
$8.77 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.05M shares |
|---|---|
| Open market or private purchase | 148K shares |
| Exercise of conversion of derivative security | 235K shares |
| Payment of exercise price or tax liability | 227K shares |
|---|---|
| Open market or private sale | 318K shares |